Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis
Top Cited Papers
Open Access
- 15 February 2022
- journal article
- review article
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 17 (1) , 1-12
Abstract
Background: A variety of mutations in the largest human gene, dystrophin, cause a spectrum from mild to severe dystrophin-associated muscular dystrophies. Duchenne (DMD) and Becker (BMD) muscular dystrophies are located at the severe end of the spectrum that primarily affects skeletal muscle. Progressive muscle weakness in these purely genetic disorders encourages families with a positive history for genetic counseling to prevent a recurrence, which requires an accurate prevalence of the disorder. Here, we provide a systematic review and meta-analysis to determine the prevalence of DMD and BMD worldwide. Method: The current systematic review and meta-analysis was carried out using Cochrane seven-step procedure. After determining the research question and inclusion and exclusion criteria, the MagIran, SID, ScienceDirect, WoS, ProQuest, Medline (PubMed), Embase, Cochrane, Scopus, and Google Scholar databases were searched to find relevant studies using defined keywords and all possible keyword combinations using the AND and OR, with no time limit until 2021. The heterogeneity of studies was calculated using the I2 test, and the publication bias was investigated using the Begg and Mazumdar rank correlation test. Statistical analysis of data was performed using Comprehensive Meta-Analysis software (version 2). Results: A total of 25 articles involving 901,598,055 people were included. The global prevalence of muscular dystrophy was estimated at 3.6 per 100,000 people (95 CI 2.8–4.5 per 100,000 people), the largest prevalence in the Americans at 5.1 per 100,000 people (95 CI 3.4–7.8 per 100,000 people). According to the subgroup analysis, the prevalence of DMD and BMD was estimated at 4.8 per 100,000 people (95 CI 3.6–6.3 per 100,000 people) and 1.6 per 100,000 people (95 CI 1.1–2.4 per 100,000 people), respectively. Conclusion: Knowing the precise prevalence of a genetic disorder helps to more accurately predict the likelihood of preventing its occurrence in families. The global prevalence of DMD and BMD was very high, indicating the urgent need for more attention to prenatal screening and genetic counseling for families with a positive history.Keywords
Funding Information
- Deputy for Research and Technology, Kermanshah University of Medical Sciences (4000159)
This publication has 50 references indexed in Scilit:
- Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic populationBrain, 2009
- Genetic epidemiology of Duchenne and Becker muscular dystrophy in SloveniaClinical Genetics, 2008
- Neuropsychiatric Disorders in Males With Duchenne Muscular Dystrophy: Frequency Rate of Attention-Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder, and Obsessive—Compulsive DisorderJournal of Child Neurology, 2008
- Glucocorticoid corticosteroids for Duchenne muscular dystrophy2008
- Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame ruleMuscle & Nerve, 2006
- Epidemiological Study of Muscular Disorders in Assiut, EgyptNeuroepidemiology, 2005
- Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrixNature, 1992
- Epidemiology of Progressive Muscular Dystrophy in Okinawa, JapanNeuroepidemiology, 1991
- Population frequencies of inherited neuromuscular diseases—A world surveyNeuromuscular Disorders, 1991
- Further studies of gene deletions that cause Duchenne and Becker muscular dystrophiesGenomics, 1988